GENERALI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.25 USD | +1.73% |
|
+1.73% | +21.75% |
| Jul. 15 | Generali buys back own shares for more than EUR16 million | AN |
| Jul. 11 | Researchers advise lessons to be learned from serious cycling accidents on country roads | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its low valuation, with P/E ratio at 9.56 and 8.78 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.85 for the current period. Therefore, the company is undervalued.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
Ratings chart - Surperformance
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +21.75% | 39.28B | - | ||
| +8.07% | 76.65B | B- | ||
| +13.39% | 53.16B | B | ||
| +14.41% | 53.8B | B+ | ||
| +24.86% | 47.66B | B+ | ||
| +21.99% | 45.43B | B+ | ||
| +18.80% | 33.57B | B | ||
| +42.95% | 29.38B | A | ||
| +1.02% | 29.33B | B | ||
| -6.52% | 27.92B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- G Stock
- ARZGF Stock
- Ratings Generali
